Law360, New York (October 28, 2009) -- A federal appeals court has reinstated a class action accusing Matrixx Initiatives Inc. of concealing from investors hundreds of consumer reports claiming cold medication Zicam caused users to lose their sense of smell.
In a ruling Wednesday, the U.S. Court of Appeals for the Ninth Circuit reversed and remanded the lawsuit, which targets Matrixx, CEO Carl Johnson, Chief Financial Officer William Hemelt and...
